Under a tenth of patients eligible to benefit from obesity jabs like Wegovy can access them, caution the global health agency as it issues its initial advice on the drugs.
With in excess of 1,000,000,000 individuals worldwide currently obese, it is urging increased and just availability to these injectable treatments.
According to forecasts, over two billion could be obese by 2030 without intervention.
"The new guidance acknowledges that excess weight is a chronic disease that can be managed with comprehensive and ongoing care," remarked the agency's head Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and supply-chain constraints are significant hurdles to broad availability to the jabs that can aid individuals in losing substantial body mass, explains the organization.
Weight-Loss Drug Scarcity
Even under the current most favorable outlook, the supply of such drugs could only cover about 100 million people – under 10% of eligible patients, as stated by the WHO.
The advice encourages nations and manufacturers to widen availability, by approaches including licensing agreements.
The intellectual property rights on a key compound – the core component of a leading brand – is due to expire in a number of countries in 2026.
How Weight-Loss Jabs Work
These medications replicate a biological compound to reduce digestion speed, suppress the appetite and boost satiety so users consume fewer calories.
Patients commonly see weight reduction after several weeks of beginning the regular doses.
Research points to people may put most of the weight back on within a year of discontinuing the medication, because their usual food cravings return.
Being carrying excess weight raises your risk for experiencing medical conditions, like diabetes, cardiovascular issues, brain attack, and some malignancies.
Obesity affects people in all nations and was linked to over three and a half million fatalities worldwide in 2024, per the health agency.
